List of Gelnique drug patents

Gelnique is owned by Allergan.

Gelnique contains Oxybutynin Chloride.

Gelnique has a total of 3 drug patents out of which 0 drug patents have expired.

Gelnique was authorised for market use on 27 January, 2009.

Gelnique is available in gel;transdermal dosage forms.

Gelnique can be used as treatment of overactive bladder by application of oxybutynin chloride gel to skin, treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel.

The generics of Gelnique are possible to be released after 26 March, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449173 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(6 years from now)

US9259388 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Nov, 2029

(6 years from now)

US8920392 ALLERGAN Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Mar, 2031

(8 years from now)

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel; Treatment of overactive bladder by application of oxybutynin chloride gel to skin

Dosage: GEL;TRANSDERMAL

How can I launch a generic of GELNIQUE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in